Author: Ken Dropiewski

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

Proceeds Will Be Used to Progress Lead Program to Phase 1 Clinical Trials and Expand Pipeline Programs CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 […]

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS–(BUSINESS WIRE)–Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today […]

Cardiovascular Systems Prices Public Offering of Common Stock

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the pricing of its previously announced underwritten public offering of 3,676,471 shares of its common stock at a price to […]

MIVI Neuroscience Announces FDA IDE Clinical Study Approval For the MIVI Q Aspiration Catheter

EDEN PRAIRIE, Minn., June 9, 2020 /PRNewswire/ — MIVI Neuroscience, a leading developer, and marketer of precision stroke therapy devices utilized by neurointerventionists around the world, announced today that the FDA has determined the company has provided sufficient data to support initiation of a human clinical study of the MIVI Q Aspiration Catheter […]

CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting

The presentation was selected as Top Bioengineering Abstract and confirms CorWave’s commitment to scientific excellence, which enabled demonstration of its Left Ventricular Assist Device’s (LVAD) capability to provide durable, long-term circulatory support with high-fidelity physiologic flow CLICHY, France–(BUSINESS WIRE)–CorWave announced today that the latest results of its preclinical Left Ventricular […]

Reflow Medical Enrolls First Patients in the DEEPER LIMUS Study of the Temporary Spur Stent System

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-RanDomized Pilot Study of the TEmporary Spur StEnt System for the Treatment of Lesions Located in the InfraPoplitEal ARteries Using a LIMUS-base Drug-coated Balloon (DEEPER LIMUS). The OUS single center clinical trial […]

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention

Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid […]

Saranas Announces Peer-Reviewed Publications Highlighting Accuracy and Clinical Utility of Early Bird® Bleed Monitoring System

HOUSTON–(BUSINESS WIRE)–Saranas, Inc., developer of the Early Bird® Bleed Monitoring System for the monitoring and early detection of internal bleed complications during endovascular procedures, announced the online publication of two peer-reviewed articles highlighting the system’s accuracy and performance. The publications provide evidence of the Early Bird’s reliability to detect the early […]

Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

FREMONT, Calif., June 8, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin Renz to the position of Chief Financial Officer. Mr. Renz, a highly accomplished leader with over 20 years of […]